Transcription Factor Inhibition: Lessons Learned and Emerging Targets

Area of Science:

• Molecular Biology
• Drug Discovery
• Genomics

Background:

• Transcription factors regulate vital cellular processes like growth, metabolism, and apoptosis.
• Dysregulated transcription factor activity is implicated in various diseases, making them key therapeutic targets.
• The inherent structural disorder and absence of binding pockets in transcription factors pose significant challenges for small molecule inhibitor design.

Purpose of the Study:

• To review recent progress in developing small molecule inhibitors for transcription factors.
• To discuss emerging transcription factor targets identified through genome-scale loss-of-function screens.
• To highlight advancements aligned with James Darnell's early vision for targeting transcription factors.

Main Methods:

• Literature review of recent developments in small molecule inhibitor research for transcription factors.
• Analysis of findings from genome-scale loss-of-function screens, particularly the cancer dependency map project.
• Synthesis of information on structural challenges and strategies for overcoming them in drug design.

Main Results:

• Significant progress has been made in designing small molecule inhibitors for transcription factors, despite initial challenges.
• New transcription factor targets have been identified through large-scale genetic screens in cancer research.
• The field is advancing towards more effective therapeutic strategies for diseases involving transcription factor dysregulation.

Conclusions:

• Targeting transcription factors with small molecules is a viable therapeutic strategy, with ongoing advancements.
• Emerging targets from cancer dependency mapping offer new avenues for drug development.
• Continued research is crucial to overcome structural hurdles and translate findings into clinical applications.